KORU Medical Systems (NASDAQ:KRMD) Posts Earnings Results, Beats Estimates By $0.03 EPS

KORU Medical Systems (NASDAQ:KRMD) released its quarterly earnings data on Thursday. The company reported $0.01 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.03, FiscalAI reports. KORU Medical Systems had a negative return on equity of 22.43% and a negative net margin of 9.49%.The firm had revenue of $10.90 million during the quarter, compared to analyst estimates of $10.90 million.

Here are the key takeaways from KORU Medical Systems’ conference call:

• CEO Linda Tharby announced her planned retirement effective June 30, 2026, with CCO Adam Kalbermatten named President on March 15 and set to become CEO on July 1, and Linda remaining as an advisor through year-end.
• KORU delivered strong financials with Q4 revenue of $10.9M (+23% YoY), full-year revenue of $41.1M (+22%), positive adjusted EBITDA (~$0.6M) and positive operating cash flow, ending 2025 with $8.9M cash.
• International momentum accelerated (Q4 international growth ~71%, full-year ~80%), and EU MDR clearance for the Freedom60 prefilled-syringe compatibility enables shipments into Europe and targets an estimated $50M addressable market.
• KORU is expanding beyond IG — received 510(k) clearance for RYSTIGGO (entry into infusion clinics), has 9 drugs on label and 9 active pipeline collaborations (including near-term vancomycin, deferoxamine, Phesgo), and guided 2026 revenue of $47.5–$50M with positive adjusted EBITDA and full-year positive cash flow.
• Headwinds include modest gross margin pressure from higher material costs, tariffs and geographic mix, a 30% decline in PST (pharma services & trials) revenue due to milestone timing, and a relatively modest year-end cash balance that could leave limited downside cushion if expected milestones or prefill conversions slip.

KORU Medical Systems Price Performance

Shares of KORU Medical Systems stock traded down $0.20 during mid-day trading on Thursday, reaching $4.31. 143,060 shares of the stock were exchanged, compared to its average volume of 196,903. KORU Medical Systems has a fifty-two week low of $1.86 and a fifty-two week high of $6.61. The company has a market cap of $199.64 million, a price-to-earnings ratio of -53.88 and a beta of 0.47. The firm has a 50-day simple moving average of $5.16 and a 200 day simple moving average of $4.80. The company has a current ratio of 2.48, a quick ratio of 1.92 and a debt-to-equity ratio of 0.01.

Institutional Trading of KORU Medical Systems

Several large investors have recently added to or reduced their stakes in KRMD. BNP Paribas Financial Markets increased its holdings in shares of KORU Medical Systems by 52.1% during the third quarter. BNP Paribas Financial Markets now owns 10,148 shares of the company’s stock worth $39,000 after buying an additional 3,478 shares in the last quarter. Lazard Asset Management LLC acquired a new position in shares of KORU Medical Systems in the 2nd quarter worth approximately $59,000. Acadian Asset Management LLC bought a new stake in KORU Medical Systems during the 1st quarter worth approximately $63,000. Invesco Ltd. bought a new stake in KORU Medical Systems during the 2nd quarter worth approximately $80,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in KORU Medical Systems during the 2nd quarter valued at $83,000. 58.60% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. Lake Street Capital lifted their target price on shares of KORU Medical Systems from $6.00 to $8.00 and gave the company a “buy” rating in a research report on Monday, December 22nd. Craig Hallum restated a “buy” rating and set a $7.00 price target on shares of KORU Medical Systems in a research note on Tuesday, January 13th. Canaccord Genuity Group lifted their price objective on KORU Medical Systems from $5.00 to $6.00 and gave the company a “buy” rating in a report on Wednesday, December 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of KORU Medical Systems in a research note on Thursday, January 22nd. Finally, Wall Street Zen raised KORU Medical Systems from a “buy” rating to a “strong-buy” rating in a report on Monday, January 12th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, KORU Medical Systems presently has a consensus rating of “Moderate Buy” and an average target price of $6.13.

KORU Medical Systems Company Profile

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products.